News & Events about Shattuck Labs Inc.
AUSTIN, TX & DURHAM, NC, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune ...
Shattuck Labs (NASDAQ:STTK) is set to give its latest quarterly earnings report on Tuesday, 2022-11-08. Here's what investors need to know before the announcement.
Analysts estimate that Shattuck Labs will report an earnings per share (EPS) of $-0.67.
read more...
Business Wire
10 months ago
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Shattuck Labs, Inc. (NASDAQ: STTK) on behalf of long-term stockholders following a class action complaint that was filed against Shattuck on February 11, 2022 with a...
Business Wire
10 months ago
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Shattuck Labs, Inc. ("Shattuck" or the "Company") (NASDAQ: STTK) and certain of its officers, on behalf of shareholders who purchased or...
Globe Newswire
10 months ago
NEW YORK, April 01, 2022 (GLOBE NEWSWIRE) -- WHY:Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Shattuck Labs, Inc. (NASDAQ: STTK): (i) pursuant and/or traceable to the registration statement and related prospectus issued in connection with Shattucks ...